1. P253 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER+/human epidermal growth factor receptor 2 (HER2)- breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study. (April 2023) Authors: Hurvitz, S.A; Schott, A.F; Ma, C.; Hamilton, E.P; Nanda, R.; Zahrah, G.; Hunter, N.; Tan, A.R; Telli, M.L; Mesias, J.A.; Jeselsohn, R.; Munster, P.; Lu, H.; Gedrich, R.; Mather, C.; Parameswaran, J.; Han, H.S; Wirth, S. Journal: Breast Issue: Volume 68(2023)Supplement Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗